Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropsychiatr Dis Treat. 2008 Jun;4(3):499-506.

Once-daily treatment of ADHD with guanfacine: patient implications.

Author information

  • 1Department of Psychiatry at The Ohio State University Columbus, OH, USA. strangeb@chi.osu.edu

Abstract

The standard of care for treating ADHD is to use a psychostimulant as the first line agent. Recent medical literature reports that approximately 70%-90% of patients with ADHD received some benefit from a stimulant medication. Even though psychostimulants have a high rate of efficacy, an estimated 30%-50% of children and adults may discontinue psychostimulants secondary to adverse effects or inadequate response. Guanfacine has been used for a number of years as an off label alternative to psychostimulants. This article reviews the current literature on the effectiveness of guanfacine in treating ADHD. It also introduces the preliminary data for guanfacine extended release and its effectiveness in decreasing the symptoms of ADHD.

KEYWORDS:

alpha adrenergic agonist; attention; attention deficit/hyperactivity disorder; guanfacine; impulsivity

PMID:
18830439
[PubMed]
PMCID:
PMC2526381
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk